GlaxoSmithKline: makes milestone payment to Epizyme
(CercleFinance.com) - GlaxoSmithKline has initiated patient dosing for a phase 1 clinical trial on a compound targeting methyltransferase that was discovered by Epizyme, prompting an 8 million dollar milestone payment to the US biotech firm.
The phase 1 study by GSK will assess the safety, pharmaco-kinetics, pharmaco-dynamics and preliminary clinical activity of GSK33368715 in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) with frequent methyl-thioadenosine phosphorylase (MTAP)-deficiency.
Methyltransferase has been involved in certain human cancers.
GSK's move marks the second program under the collaboration agreement with Epizyme to enter a clinical trial.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The phase 1 study by GSK will assess the safety, pharmaco-kinetics, pharmaco-dynamics and preliminary clinical activity of GSK33368715 in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) with frequent methyl-thioadenosine phosphorylase (MTAP)-deficiency.
Methyltransferase has been involved in certain human cancers.
GSK's move marks the second program under the collaboration agreement with Epizyme to enter a clinical trial.
Copyright (c) 2018 CercleFinance.com. All rights reserved.